Celldex Therapeutics CLDX Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's free cash flow yield?
- Celldex Therapeutics (CLDX) reported free cash flow yield of -10.7% in Q1 2026.
- How has Celldex Therapeutics's free cash flow yield changed year-over-year?
- Celldex Therapeutics's free cash flow yield increased by 25.5% year-over-year, from -14.4% to -10.7%.
- What is the long-term trend for Celldex Therapeutics's free cash flow yield?
- Over 5 years (2020 to 2025), Celldex Therapeutics's free cash flow yield has grown at a 18.2% compound annual growth rate (CAGR), from -5.1% to -11.8%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.